—
C+
C+ The full Closelook — membership. Open the C+ overview

HUTCHMED China Ltd (HCM.L) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — HUTCHMED China Ltd

HCM.L in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
HUTCHMED China discovers, develops and sells targeted cancer therapies and immunology drugs, working across Hong Kong, the United States and other markets. Its lead approved medicine, fruquintinib, blocks blood-vessel growth signals in several solid tumours, and it has other compounds in development for lymphomas and leukaemias. It partners with larger drugmakers such as AstraZeneca and Takeda to help fund and commercialise some of these programmes. The company is based in Hong Kong.
Where it sits in the stack
HUTCHMED sits outside our AI-build-out coverage; within our universe it belongs to the Healthcare sleeve, in the specialty and generic drug-manufacturing group rather than any semiconductor or infrastructure layer.
Who it is priced against
Closelook has not assigned it to a peer group yet; the diary places it loosely among oncology-focused biotech developers, a set the market often compares with BeiGene.
Why Closelook tracks it
It holds no seat in our index and carries no Closelook score yet, and the diary has not quoted it in an edition so far.
What the diary watches
Whether trial results or new partnership deals for its pipeline compounds shift its commercial outlook enough to warrant closer coverage.

HUTCHMED China Ltd (HCM.L) trades on the LSE exchange in UK.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for HCM.L, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against HCM.L on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is HUTCHMED China Ltd (HCM.L)?

HUTCHMED China Ltd trades as HCM.L on the LSE exchange (UK) in the Closelook research universe, as of the registry build of 2026-09-18.

Is HCM.L in a Closelook index?

Not currently — HUTCHMED China Ltd is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does HCM.L trade against its moving averages?

Recovery attempt under the 200-day: Trades +13.1% vs the 50-day and +5.6% vs the 200-day average, 20.1% below the 52-week high and +37.6% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does HUTCHMED China Ltd do?

HUTCHMED China discovers, develops and sells targeted cancer therapies and immunology drugs, working across Hong Kong, the United States and other markets. Its lead approved medicine, fruquintinib, blocks blood-vessel growth signals in several solid tumours, and it has other compounds in development for lymphomas and leukaemias. It partners with larger drugmakers such as AstraZeneca and Takeda to help fund and commercialise some of these programmes. Closelook has not assigned it to a peer group yet; the diary places it loosely among oncology-focused biotech developers, a set the market often compares with BeiGene.

Where does HUTCHMED China Ltd sit in the AI build-out?

HUTCHMED sits outside our AI-build-out coverage; within our universe it belongs to the Healthcare sleeve, in the specialty and generic drug-manufacturing group rather than any semiconductor or infrastructure layer. It holds no seat in our index and carries no Closelook score yet, and the diary has not quoted it in an edition so far.

What does this page show?

A live price chart with SMA overlays and drawing tools for HCM.L, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.